Refine Search

Search Results -

Terms	Documents
L12 and L4	196

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L13

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Monday, May 17, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT; PLUR=YES; OP=OR		
L13	L12 and l4	196	L13
L12	L11 and l2	351	L12
L11	L10 and IgG	3815	L11
L10	L9 and IgA	4355	L10
L9	L8 and light chain	473912	L9
L8	L7 and protease	16551	L8
L7	L6 and inhibition	64861	L7
L6	L4 and mast cell degranulation	445765	L6
L5	L4 and mast cell degranualtion	445730	L5
L4	neisseria gonorrhoeae	3206	L4
L3	tetanus toxin	21805	L3
L2	clostridium botulinum	4939	L2
L1	bigalke.in.	16	L1

h e b b cg b e e ch

END OF SEARCH HISTORY

h e b b cg b e e ch

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:15:39 ON 17 MAY 2004

```
=> file medline, uspatful, dgene, embase, wpids, fsta, hcaplus, jicst,
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'MEDLINE' ENTERED AT 11:16:09 ON 17 MAY 2004

FILE 'USPATFULL' ENTERED AT 11:16:09 ON 17 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:16:09 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 11:16:09 ON 17 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 11:16:09 ON 17 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 11:16:09 ON 17 MAY 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'HCAPLUS' ENTERED AT 11:16:09 ON 17 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JICST-EPLUS' ENTERED AT 11:16:09 ON 17 MAY 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

=> s hybrid protein and protease
L1          2882 HYBRID PROTEIN AND PROTEASE

=> s hybrid protein and antibody
L2          6604 HYBRID PROTEIN AND ANTIBODY

=> s l2 and l1
L3          2111 L2 AND L1

=> s l3 and IgG
L4          1445 L3 AND IGG

=> s clostridum botulinum neurotoxin
L5             0 CLOSTRIDUM BOTULINUM NEUROTOXIN

=> s clostridum botulinum
L6            37 CLOSTRIDUM BOTULINUM

=> s l6 and l4
L7             0 L6 AND L4

=> s l6 and mast cell
L8             1 L6 AND MAST CELL

=> d l8 ti abs ibib tot

L8   ANSWER 1 OF 1  WPIDS  COPYRIGHT 2004 THOMSON DERWENT on STN
TI   New hybrid protein useful for inhibiting mast cell
     degranulation and treating allergic reactions.
AN   2000-072332 [06]   WPIDS
AB   WO   9958571 A UPAB: 20000203
     NOVELTY - A protein which binds to, or is absorbed by, mast cells or
     basophils is combined with a known protease (which cleaves proteins of the
     secretory apparatus of such cells) in a hybrid protein which is useful for
```

inhibiting **mast cell** degranulation and treating allergic reactions.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: (A) hybrid protein comprising: (a) a known protein which binds to (or is absorbed by) mast cells and/or basophils, in a known manner; and (b) a known protease which cleaves one or more proteins of the secretory apparatus of the mast cells or basophils. (B) hybrid protein comprising: (a) a protein which binds to (or is absorbed by) mast cells or basophils; and (b) a protease (especially a known protease) which cleaves one or more proteins of the secretory apparatus of the mast cells or basophils. Component (a) is selected from (i) IgE, (ii) IgE fragments (especially an IgE-Fc fragment), (iii) antibodies against IgE receptors of mast cells and/or basophils, (iv) fragments of antibodies against IgE receptors of mast cells and/or basophils (especially an Fab fragment), (v) antibodies against the **mast cell**-specific potassium channel, and (vi) inactive (though binding) MCD peptide. (C) hybrid protein comprising: (a) a protein (especially a known protein) which binds to (or is absorbed by) mast cells and/or basophils; and (b) a protease which cleaves one or more proteins of the secretion apparatus of the mast cells or basophils. The protease is selected from (i) the light chain of a **Clostridum botulinum** toxin (especially type A, B, Cl, D, E, F or G), (ii) the light chain of Tetanus toxin, (iii) catalytically active fragments of the light chains described in (i) or (ii), (iv) IgA protease from Neisseria gonorrhea or (v) catalytic domains of IgA protease from Neisseria gonorrhea.

ACTIVITY - Antiallergic.

USE - The hybrid proteins inhibit **mast cell** degranulation, and may be used in treatment or prevention of allergic reactions.

Dwg.0/0

ACCESSION NUMBER: 2000-072332 [06] WPIDS
DOC. NO. CPI: C2000-020614
TITLE: New hybrid protein useful for inhibiting **mast cell** degranulation and treating allergic reactions.
DERWENT CLASS: B04 D16 J04
INVENTOR(S): BIGALKE, H; FREVERT, J
PATENT ASSIGNEE(S): (BIOT-N) BIOTECON-GES BIOTECHNOLOGISCHE; (BIET-N) BIETECON GES BIOTECHNOLOGISCHE ENTWICKLU; (BIOT-N) BIOTECON-GES BIOTECHNOLOGISCHE ENTWICKLU
COUNTRY COUNT: 87
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9958571	A2	19991118	(200006)*	GE	22
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW					
AU 9942605	A	19991129	(200018)		
BR 9910359	A	20010109	(200106)		
NO 2000005637	A	20001108	(200108)		
EP 1084146	A2	20010321	(200117)	GE	
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE					
CZ 2000004161	A3	20010411	(200130)		
CN 1300295	A	20010620	(200159)		
KR 2001042825	A	20010525	(200168)		
HU 2001003601	A2	20020128	(200222)		
JP 2002514659	W	20020521	(200236)		22
EP 1084146	B1	20021113	(200282)	GE	
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE					

DE 59903410	G	20021219 (200302)
AU 755513	B	20021212 (200305)
US 2003059912	A1	20030327 (200325)
ES 2187200	T3	20030516 (200337)
RU 2214420	C2	20031020 (200380)
MX 2000011148	A1	20030401 (200415)

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9958571	A2		WO 1999-EP3272	19990512
AU 9942605	A		AU 1999-42605	19990512
BR 9910359	A		BR 1999-10359	19990512
			WO 1999-EP3272	19990512
NO 2000005637	A		WO 1999-EP3272	19990512
			NO 2000-5637	20001108
EP 1084146	A2		EP 1999-950347	19990512
			WO 1999-EP3272	19990512
CZ 2000004161	A3		WO 1999-EP3272	19990512
			CZ 2000-4161	19990512
CN 1300295	A		CN 1999-806061	19990512
KR 2001042825	A		KR 2000-711584	20001018
HU 2001003601	A2		WO 1999-EP3272	19990512
			HU 2001-3601	19990512
JP 2002514659	W		WO 1999-EP3272	19990512
			JP 2000-548373	19990512
EP 1084146	B1		EP 1999-950347	19990512
			WO 1999-EP3272	19990512
DE 59903410	G		DE 1999-503410	19990512
			EP 1999-950347	19990512
			WO 1999-EP3272	19990512
AU 755513	B		AU 1999-42605	19990512
US 2003059912	A1	CIP of	WO 1999-EP3272	19990512
		CIP of	US 2001-700540	20010119
			US 2002-64903	20020827
ES 2187200	T3		EP 1999-950347	19990512
RU 2214420	C2		WO 1999-EP3272	19990512
			RU 2000-131217	19990512
MX 2000011148	A1		WO 1999-EP3272	19990512
			MX 2000-11148	20001113

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9942605	A	Based on	WO 9958571
BR 9910359	A	Based on	WO 9958571
EP 1084146	A2	Based on	WO 9958571
CZ 2000004161	A3	Based on	WO 9958571
HU 2001003601	A2	Based on	WO 9958571
JP 2002514659	W	Based on	WO 9958571
EP 1084146	B1	Based on	WO 9958571
DE 59903410	G	Based on	EP 1084146
		Based on	WO 9958571
AU 755513	B	Previous Publ.	AU 9942605
		Based on	WO 9958571
ES 2187200	T3	Based on	EP 1084146
RU 2214420	C2	Based on	WO 9958571
MX 2000011148	A1	Based on	WO 9958571

PRIORITY APPLN. INFO: DE 1998-19821285 19980513

```
=> d his

     (FILE 'HOME' ENTERED AT 11:15:39 ON 17 MAY 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, HCAPLUS,
     JICST-EPLUS' ENTERED AT 11:16:09 ON 17 MAY 2004
L1          2882 S HYBRID PROTEIN AND PROTEASE
L2          6604 S HYBRID PROTEIN AND ANTIBODY
L3          2111 S L2 AND L1
L4          1445 S L3 AND IGG
L5             0 S CLOSTRIDUM BOTULINUM NEUROTOXIN
L6            37 S CLOSTRIDUM BOTULINUM
L7             0 S L6 AND L4
L8             1 S L6 AND MAST CELL

=> s l4 and mastocyte
L9             0 L4 AND MASTOCYTE

=> s l4 and basophil
L10           21 L4 AND BASOPHIL

=> d l10 ti abs ibib tot

L10  ANSWER 1 OF 21  USPATFULL on STN
TI     Therapeutic polypeptides, nucleic acids encoding same, and methods of
       use
AB     Disclosed herein are nucleic acid sequences that encode novel
       polypeptides. Also disclosed are polypeptides encoded by these nucleic
       acid sequences, and antibodies that immunospecifically bind to the
       polypeptide, as well as derivatives, variants, mutants, or fragments of
       the novel polypeptide, polynucleotide, or antibody specific to
       the polypeptide. Vectors, host cells, antibodies and recombinant methods
       for producing the polypeptides and polynucleotides, as well as methods
       for using same are also included. The invention further discloses
       therapeutic, diagnostic and research methods for diagnosis, treatment,
       and prevention of disorders involving any one of these novel human
       nucleic acids and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2004:88520  USPATFULL
TITLE:                    Therapeutic polypeptides, nucleic acids encoding same,
                          and methods of use
INVENTOR(S):              Zhong, Mei, Branford, CT, UNITED STATES
                          Li, Li, Branford, CT, UNITED STATES
                          Gorman, Linda, Branford, CT, UNITED STATES
                          Spytek, Kimberly A., New Haven, CT, UNITED STATES
                          Kekuda, Ramesh, Norwalk, CT, UNITED STATES
                          Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
                          Anderson, David W., Branford, CT, UNITED STATES
                          Vernet, Corine A.M., Branford, CT, UNITED STATES
                          Catterton, Elina, Madison, CT, UNITED STATES
                          Miller, Charles E., Guilford, CT, UNITED STATES
                          Shenoy, Suresh G., Branford, CT, UNITED STATES
                          Patturajan, Meera, Branford, CT, UNITED STATES
                          Pena, Carol E. A., New Haven, CT, UNITED STATES
                          Tchernev, Velizar T., Branford, CT, UNITED STATES
                          Padigaru, Muralidhara, Branford, CT, UNITED STATES
                          Gusev, Vladimir Y., Madison, CT, UNITED STATES
                          Malyankar, Uriel M., Branford, CT, UNITED STATES
                          Burgess, Catherine E., Wethersfield, CT, UNITED STATES
                          Gerlach, Valerie, Branford, CT, UNITED STATES
                          Casman, Stacie J., North Haven, CT, UNITED STATES
                          Rieger, Daniel K., Branford, CT, UNITED STATES
                          Grosse, William M., Branford, CT, UNITED STATES
```

Smithson, Glennda, Guilford, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Starling, Gary, Middletown, CT, UNITED STATES
Rothenberg, Mark E., Clinton, CT, UNITED STATES
LaRochelle, William J., Madison, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Crabtree, Julie, Gainesville, FL, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Voss, Edward Z., Wallingford, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Chapoval, Andrei, Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004067490	A1	20040408
APPLICATION INFO.:	US 2002-236392	A1	20020906 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-390155P	20020619 (60)
	US 2001-318765P	20010912 (60)
	US 2002-357303P	20020215 (60)
	US 2002-367753P	20020325 (60)
	US 2002-369479P	20020402 (60)
	US 2001-318120P	20010907 (60)
	US 2001-318130P	20010907 (60)
	US 2002-381672P	20020517 (60)
	US 2001-318219P	20010907 (60)
	US 2001-318430P	20010910 (60)
	US 2001-322781P	20010917 (60)
	US 2001-322816P	20010917 (60)
	US 2001-323519P	20010919 (60)
	US 2002-384012P	20020529 (60)
	US 2001-323631P	20010920 (60)
	US 2001-323636P	20010920 (60)
	US 2002-360973P	20020228 (60)
	US 2002-366131P	20020320 (60)
	US 2001-324969P	20010925 (60)
	US 2002-383651P	20020528 (60)
	US 2001-325091P	20010925 (60)
	US 2001-324990P	20010926 (60)
	US 2002-381664P	20020517 (60)
	US 2002-379532P	20020510 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN,, FERRIS, GLOVSKY and POPEO, P.C., One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 36918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 21 USPATFULL on STN
TI Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof
AB Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:85166 USPATFULL

TITLE: Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof

INVENTOR(S): Donoho, Gregory, Portage, MI, United States
Turner, Jr., C. Alexander, The Woodlands, TX, United States
Nehls, Michael C., Stockdorf, GERMANY, FEDERAL REPUBLIC OF
Friedrich, Glenn, Houston, TX, United States
Zambrowicz, Brian, The Woodlands, TX, United States
Sands, Arthur T., The Woodlands, TX, United States

PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, Woodlands, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6716614	B1	20040406	
APPLICATION INFO.:	US 2002-202619		20020723	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-653839, filed on 1 Sep 2000, now patented, Pat. No. US 6433153

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-152057P	19990902 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Achutamurthy, P.
ASSISTANT EXAMINER: Pak, Yong
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3576
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 21 USPATFULL on STN

TI Segments of the human gene for telomerase reverse transcriptase

AB The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:289308 USPATFULL

TITLE: Segments of the human gene for telomerase reverse transcriptase

INVENTOR(S): Morin, Gregg B., Toronto, CANADA
Andrews, William H., Reno, NV, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003204069	A1	20031030	
APPLICATION INFO.:	US 2002-325810	A1	20021220	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-402181, filed on 29 Sep 1999, PENDING A 371 of International Ser. No. WO 1997-US17885, filed on 1 Oct 1997, PENDING Continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997, GRANTED, Pat. No. US 6475789 Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 103 Drawing Page(s)
LINE COUNT: 10647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 21 USPATFULL on STN
TI Cells immortalized with telomerase reverse transcriptase for use in drug screening
AB The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:240307 USPATFULL
TITLE: Cells immortalized with telomerase reverse transcriptase for use in drug screening
INVENTOR(S): Cech, Thomas R., Boulder, CO, United States
Lingner, Joachim, Epalinges, SWITZERLAND
Nakamura, Toru, Boulder, CO, United States
Chapman, Karen B., Sausalito, CA, United States
Morin, Gregg B., Palo Alto, CA, United States
Harley, Calvin B., Palo Alto, CA, United States
Andrews, William H., Richmood, CA, United States
PATENT ASSIGNEE(S): Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
University Technology Corporation, Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6617110	B1	20030909
APPLICATION INFO.:	US 2000-721456		20001124 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-974549, filed on 19 Nov 1997, now patented, Pat. No. US 6166178 Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned Continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997, now patented, Pat. No. US 6475789 Continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997, now abandoned Continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997, now patented, Pat. No. US 6261836 Continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997, now patented, Pat. No. US 6093809 Continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Walicka, M.
LEGAL REPRESENTATIVE: Schiff, J. Michael, Earp, David J., Ausenhus, Scott L.
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 77 Drawing Figure(s); 103 Drawing Page(s)
LINE COUNT: 11102
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 21 USPATFULL on STN
TI Promoter for telomerase reverse transcriptase
AB The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of humana diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:228405 USPATFULL		
TITLE:	Promoter for telomerase reverse transcriptase		
INVENTOR(S):	Morin, Gregg B., Davis, CA, United States Andrews, William H., Richmond, CA, United States		
PATENT ASSIGNEE(S):	Geron Corporation, Menlo Park, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6610839	B1	20030826
	WO 9814593		19980409
APPLICATION INFO.:	US 1999-402181		19990929 (9)
	WO 1997-US17885		19971001
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997 Continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997, now abandoned Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Prouty, Rebecca E.		
ASSISTANT EXAMINER:	Walicka, Malgorzata A.		
LEGAL REPRESENTATIVE:	Schiff, J. Michael, Earp, David J.		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	78 Drawing Figure(s); 103 Drawing Page(s)		
LINE COUNT:	10430		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 21 USPATFULL on STN
TI Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection
AB The present invention relates to the discovery of molecules that inhibit viral infection and promote a host immune response to a pathogen. More specifically, the invention disclosed herein concerns molecules that interact with a FPR class receptor, inhibit HIV infection, and stimulate an inflammatory response in a subject. Embodiments of the invention include biotechnological tools, prophylactics, therapeutics, and methods of use of the foregoing, for the study, treatment, and prevention of HIV infection and the induction of an inflammatory response in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:213246 USPATFULL
TITLE:	Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection
INVENTOR(S):	Wang, Ji-Ming, Frederick, MD, UNITED STATES Le, Yingying, Frederick, MD, UNITED STATES Gong, WangHua, Frederick, MD, UNITED STATES Li, Bao Qun, Frederick, MD, UNITED STATES Rogers, Thomas, North Wales, PA, UNITED STATES Murphy, Philip, Rockville, MD, UNITED STATES Oppenheim, Joost J., Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003147883	A1	20030807	
APPLICATION INFO.:	US 2002-199228	A1	20020717	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-US2842, filed on 4 Feb 2000, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Page(s)
LINE COUNT: 2702
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 21 USPATFULL on STN
TI Novel human proteins, polynucleotides encoding them and methods of using the same

AB The invention provides polypeptides, designated herein as POLYX polypeptides, as well as polynucleotides encoding POLYX polypeptides, and antibodies that immunospecifically-bind to POLYX polypeptide or polynucleotide, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which the POLYX polypeptide, polynucleotide, and **antibody** are used in the detection, prevention, and treatment of a broad range of pathological states.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:201372 USPATFULL
TITLE: Novel human proteins, polynucleotides encoding them and methods of using the same
INVENTOR(S): Spytek, Kimberly A., New Haven, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Smithson, Glennda, Branford, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003139358	A1	20030724	
APPLICATION INFO.:	US 2001-849138	A1	20010504	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-201951P	20000505	(60)
	US 2000-215857P	20000703	(60)
	US 2001-265162P	20010130	(60)
	US 2000-203109P	20000508	(60)
	US 2000-203295P	20000511	(60)
	US 2000-210055P	20000607	(60)
	US 2000-204064P	20000512	(60)
	US 2000-204063P	20000512	(60)
	US 2000-204062P	20000512	(60)
	US 2000-203838P	20000512	(60)
	US 2000-203839P	20000512	(60)
	US 2000-204089P	20000515	(60)
	US 2000-204276P	20000516	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C., One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 8381
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 21 USPATFULL on STN
TI Diagnostic kit for detecting immunogenic response and method of screening
AB The present invention relates to a kit for predicting binding of specific antibodies to potential immunogens. The kit comprises antigenic peptide sequences having less than 26 amino acids, said antigenic peptide sequences being capable of binding antibodies specific for structural epitopes contained on potential immunogens. The antigenic peptide sequences are immobilized on a solid support.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:173222 USPATFULL
TITLE: Diagnostic kit for detecting immunogenic response and method of screening
INVENTOR(S): Roggen, Erwin Ludo, Lyngby, DENMARK
Nilsson, Nina Teeres, Kavlinge, SWEDEN
Ernst, Steffen, Bronshoj, DENMARK
Patkar, Shamkant Anant, Lyngby, DENMARK
Friis, Esben Peter, UNITED STATES
PATENT ASSIGNEE(S): Novozymes A/S, Bagsvaerd, DENMARK (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003119066	A1	20030626	
APPLICATION INFO.:	US 2002-264559	A1	20021004	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	DK 2001-1473	20011005	
	US 2001-330289P	20011018	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOVOZYMES NORTH AMERICA, INC., 500 FIFTH AVENUE, SUITE 1600, NEW YORK, NY, 10110
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1478
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 21 USPATFULL on STN
TI Human telomerase catalytic subunit: diagnostic and therapeutic methods
AB The present invention is directed to cells comprising a recombinant polynucleotide sequence that encodes a telomerase reverse transcriptase protein, variant, or fragment having telomerase catalytic activity when complexed with a telomerase RNA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:146347 USPATFULL
TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods
INVENTOR(S): Cech, Thomas R., Boulder, CO, UNITED STATES
Lingner, Joachim, Pl. Croix-Blanche, SWITZERLAND
Nakamura, Toru, Boulder, CO, UNITED STATES
Chapman, Karen B., Sausalito, CA, UNITED STATES
Morin, Gregg B., Davis, CA, UNITED STATES

Harley, Calvin B., Palo Alto, CA, UNITED STATES
Andrews, William H., Richmond, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003100093	A1	20030529
APPLICATION INFO.:	US 2002-44539	A1	20020111 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-912951, filed on 14 Aug 1997, PENDING Continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997, GRANTED, Pat. No. US 6261836 Continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997, GRANTED, Pat. No. US 6093809 Continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 11968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 21 USPATFULL on STN
TI Human telomerase catalytic subunit: diagnostic and therapeutic methods
AB The present invention is directed to pharmaceutical compositions comprising a telomerase reverse transcriptase polypeptide or a polypeptide homologous to a telomerase reverse transcriptase. The present invention is also directed to pharmaceutical compositions comprising a polynucleotide encoding either of the aforesaid polypeptides. The present invention is further directed to methods for eliciting an immune response to telomerase reverse transcriptase in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:140503 USPATFULL
TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods
INVENTOR(S): Cech, Thomas R., Boulder, CO, UNITED STATES
Lingner, Joachim, PI. Croix-Blanche 25, SWITZERLAND
Nakamura, Toru, Boulder, CO, UNITED STATES
Chapman, Karen B., Sausalito, CA, UNITED STATES
Morin, Gregg B., Davis, CA, UNITED STATES
Harley, Calvin B., Palo Alto, CA, UNITED STATES
Andrews, William H., Richmond, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096344	A1	20030522
APPLICATION INFO.:	US 2002-44692	A1	20020111 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-912951, filed on 14 Aug 1997, PENDING Continuation of Ser. No. US 1997-854050, filed on 9 May 1997, GRANTED, Pat. No. US 6261836 Continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997, GRANTED, Pat. No. US 6093809 Continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 7257
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 21 USPATFULL on STN
TI Mouse cytokine receptor
AB Cytokines and their receptors have proven usefulness in both basic research, animal models, and as therapeutics. The present invention provides a new cytokine receptor designated as "mouse Zcytor16," which can bind and antagonize the IL-TIF cytokine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:112973 USPATFULL
TITLE: Mouse cytokine receptor
INVENTOR(S): Presnell, Scott R., Tacoma, WA, UNITED STATES
Xu, Wenfeng, Mukilteo, WA, UNITED STATES
Kindsvogel, Wayne, Seattle, WA, UNITED STATES
Chen, Zhi, Bellevue, WA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003077706	A1	20030424	
APPLICATION INFO.:	US 2002-90365	A1	20020304	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-273035P	20010302	(60)
	US 2001-279232P	20010327	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jennifer K. Johnson, J.D., ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 7834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 21 USPATFULL on STN
TI Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
AB Disclosed are recombinant hybrid proteins having at least one antigenic peptide sequence introduced into a scaffold protein that retain a native conformation. Also disclosed are recombinant nucleic acids and vectors encoding the hybrid proteins. The hybrid proteins retain immunogenicity but exhibit reduced allergenicity. The hybrid proteins are therefore particularly useful for therapeutic treatment of allergy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:57096 USPATFULL
TITLE: Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
INVENTOR(S): King, Te Piao, New York, NY, UNITED STATES
Spangfort, Michael Dho, Viken, SWEDEN
PATENT ASSIGNEE(S): The Rockefeller University (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2003039660	A1	20030227
APPLICATION INFO.:	US 2002-91135	A1	20020304 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-272818P	20010302 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DARBY & DARBY P.C., 805 Third Avenue, New York, NY, 10022
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 7866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 21 USPATFULL on STN
TI Polynucleotides encoding human eosinophil-derived basic protein
AB The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and agonists, antibodies or antagonists specifically binding EBPH, in the prevention and treatment of diseases associated with expression of EBPH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding EBPH for the treatment of diseases associated with the expression of EBPH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding EBPH.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:326110 USPATFULL
TITLE: Polynucleotides encoding human eosinophil-derived basic protein
INVENTOR(S): Akerblom, Ingrid E., Redwood City, CA, United States
PATENT ASSIGNEE(S): Incyte Genomics, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6492507	B1	20021210
APPLICATION INFO.:	US 1996-740036		19961023 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Incyte Genomics, Inc.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 21 USPATFULL on STN
TI Human telomerase catalytic subunit: diagnostic and therapeutic methods
AB The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis, and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:290772 USPATFULL

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

INVENTOR(S): Cech, Thomas R., Boulder, CO, United States
Lingner, Joachim, Epalinges, SWITZERLAND
Nakamura, Toru, Boulder, CO, United States
Chapman, Karen B., Sausalito, CA, United States
Morin, Gregg B., Palo Alto, CA, United States
Harley, Calvin B., Palo Alto, CA, United States
Andrews, William H., Richmond, CA, United States

PATENT ASSIGNEE(S): University Technology Corporation, Boulder, CO, United States (U.S. corporation)
Geron Corporation, Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6475789	B1	20021105
APPLICATION INFO.:	US 1997-912951		19970814 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-845050, filed on 9 May 1997, now patented, Pat. No. US 5743518
Continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997, now patented, Pat. No. US 6093809
Continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Eyler, Yvonne
ASSISTANT EXAMINER: Andres, Janet L.
LEGAL REPRESENTATIVE: Schiff, J. Michael, Earp, David J., Ausenhus, Scott L.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 11405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 15 OF 21 USPATFULL on STN

TI Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death

AB The present invention relates to compositions and methods for the treatment and diagnosis of conditions, disorders, or diseases involving cell death. The invention encompasses protective nucleic acids which, when introduced into a cell predisposed to undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous nucleic acids have been introduced. The invention encompasses nucleic acids of the protective sequence, host cell expression systems of the protective sequence, and hosts that have been transformed by these expression systems, including transgenic animals. The invention also encompasses novel protective sequence products, including proteins, polypeptides and peptides containing amino acid sequences of the proteins, fusion proteins of proteins, polypeptides and peptides, and antibodies directed against such gene products. The invention further relates to target sequences, including upstream and downstream regulatory sequences or complete gene sequences, antibodies, antisense molecules or sequences, ribozyme molecules, and other inhibitors or modulators directed against such protective sequences, protective sequence products, genes, gene products, and/or their regulatory elements involved in cell death. The present invention also relates to methods and compositions for the diagnosis and treatment of conditions,

disorders, or diseases, involving cell death, including, but not limited to, treatment of the types of conditions, disorders, or diseases, which can be prevented, delayed or rescued from cell death and include, but are not limited to, those associated with the central nervous system, including neurological and psychiatric conditions, disorders, or diseases, and those of the peripheral nervous system. Further, the invention relates to methods of using the protective sequence, protective sequence products, and/or their regulatory elements for the identification of compounds that modulate the expression of the protective sequence and/or the activity of the protective sequence product. Such compounds can be useful as therapeutic agents in the treatment of various conditions, disorders, or diseases involving cell death.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:206770 USPATFULL
TITLE:	Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
INVENTOR(S):	Lo, Donald C., Chapel Hill, NC, UNITED STATES Barney, Shawn, Apex, NC, UNITED STATES Thomas, Mary Beth, Chapel Hill, NC, UNITED STATES Portbury, Stuart D., Durham, NC, UNITED STATES Puranam, Kasturi, Durham, NC, UNITED STATES Katz, Lawrence C., Durham, NC, UNITED STATES
PATENT ASSIGNEE(S):	COGENT NEUROSCIENCE, INC., DURHAM, NC, UNITED STATES, 27704 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002111471	A1	20020815	
APPLICATION INFO.:	US 2001-922261	A1	20010803	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-461697, filed on 14 Dec 1999, PATENTED			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	PENNIE & EDMONDS LLP, 1155 Avenue of the Americas, New York, NY, 10036-2711			
NUMBER OF CLAIMS:	55			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	92 Drawing Page(s)			
LINE COUNT:	8075			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 21 USPATFULL on STN

TI Human cytokine receptor

AB Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as "Zcytor16."

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:21834 USPATFULL
TITLE:	Human cytokine receptor
INVENTOR(S):	Presnell, Scott R, Tacoma, WA, UNITED STATES Xu, Wenfeng, Mukilteo, WA, UNITED STATES Kindsvogel, Wayne, Seattle, WA, UNITED STATES Chen, Zhi, Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002012669	A1	20020131	
APPLICATION INFO.:	US 2000-728911	A1	20001201	(9)

NUMBER	DATE

PRIORITY INFORMATION: US 1999-169049P 19991203 (60)
US 2000-232219P 20000913 (60)
US 2000-244610P 20001031 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jennifer K Johnson J D, ZymoGenetics Inc, 1201 Eastlake Avenue East, Seattle, WA, 98102
NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
LINE COUNT: 7478
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 21 USPATFULL on STN
TI Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AB The present invention relates to compositions and methods for the treatment and diagnosis of conditions, disorders, or diseases involving cell death. The invention encompasses protective nucleic acids which, when introduced into a cell predisposed to undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous nucleic acids have been introduced. The invention encompasses nucleic acids of the protective sequence, host cell expression systems of the protective sequence, and hosts that have been transformed by these expression systems, including transgenic animals. The invention also encompasses novel protective sequence products, including proteins, polypeptides and peptides containing amino acid sequences of the proteins, fusion proteins of proteins, polypeptides and peptides, and antibodies directed against such gene products. The invention further relates to target sequences, including upstream and downstream regulatory sequences or complete gene sequences, antibodies, antisense molecules or sequences, ribozyme molecules, and other inhibitors or modulators directed against such protective sequences, protective sequence products, genes, gene products, and/or their regulatory elements involved in cell death. The present invention also relates to methods and compositions for the diagnosis and treatment of conditions, disorders, or diseases, involving cell death, including, but not limited to, treatment of the types of conditions, disorders, or diseases, which can be prevented, delayed or rescued from cell death and include, but are not limited to, those associated with the central nervous system, including neurological and psychiatric conditions, disorders, or diseases, and those of the peripheral nervous system. Further, the invention relates to methods of using the protective sequence, protective sequence products, and/or their regulatory elements for the identification of compounds that modulate the expression of the protective sequence and/or the activity of the protective sequence product. Such compounds can be useful as therapeutic agents in the treatment of various conditions, disorders, or diseases involving cell death.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:136775 USPATFULL
TITLE: Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
INVENTOR(S): Lo, Donald C., Chapel Hill, NC, United States
Barney, Shawn, Apex, NC, United States
Thomas, Mary Beth, Chapel Hill, NC, United States
Portbury, Stuart D., Durham, NC, United States
Puranam, Kasturi, Durham, NC, United States
Katz, Lawrence C., Durham, NC, United States
PATENT ASSIGNEE(S): Cogent Neuroscience, Inc., Durham, NC, United States (U.S. corporation)

NUMBER KIND DATE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6277974	B1	20010821	
APPLICATION INFO.:	US 1999-461697		19991214	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Robinson, Patricia
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 262 Drawing Figure(s); 92 Drawing Page(s)
LINE COUNT: 4670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 18 OF 21 USPATFULL on STN
TI Monoclonal **antibody** antagonists to IL-3
AB Anti IL-3 Receptor alpha chain monoclonal **antibody** (MoAb) is the product of a hybridoma cell line designated 7G3. The MoAb acts as an antagonist to IL-3 in vitro activity. The MoAb binds to the N terminal domain of the IL-3 receptor alpha chain and does so competitively with IL-3 which indicates that this is, at least in part, involved in IL-3 binding. Treatment with the MoAb or fragment thereof, whether recombinant or otherwise, may be suitable for the treatment of one or more of the following conditions: myeloid leukemias, lymphomas such as follicular B cell lymphoma, or the alleviation of allergies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:10540 USPATFULL
TITLE: Monoclonal **antibody** antagonists to IL-3
INVENTOR(S): Lopez, Angel F, Adelaide, Australia
PATENT ASSIGNEE(S): Medvet Science Pty Limited, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6177078	B1	20010123	
	WO 9724373		19970710	
APPLICATION INFO.:	US 1998-101162		19980629	(9)
	WO 1996-AU840		19961224	
			19980629	PCT 371 date
			19980629	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1995-7368	19951229
	AU 1996-7418	19960104

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Mertz, Prema
ASSISTANT EXAMINER: Hamud, Fozia
LEGAL REPRESENTATIVE: Coleman, Henry D., Sudol, R. Neil
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 755
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 21 USPATFULL on STN
TI Telomerase catalytic subunit
AB The invention provides compositions and methods related to telomerase reverse transcriptase, the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for

treatment of diseases such as cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:174804 USPATFULL
TITLE: Telomerase catalytic subunit
INVENTOR(S): Cech, Thomas R., Boulder, CO, United States
Lingner, Joachim, Boulder, CO, United States
PATENT ASSIGNEE(S): University Technology Corporation, Boulder, CO, United States (U.S. corporation)
Geron Corporation, Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6166178		20001226
APPLICATION INFO.:	US 1997-974549		19971119 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned And a continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997 And a continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997 which is a continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997 which is a continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997 which is a continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997 which is a continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1997-US17618	19971001
	WO 1997-US17885	19971001

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eyler, Yvonne
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 128 Drawing Figure(s); 103 Drawing Page(s)
LINE COUNT: 23874
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 20 OF 21 USPATFULL on STN
TI Human eosinophil-derived basic protein
AB The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and agonists, antibodies or antagonists specifically binding EBPH, in the prevention and treatment of diseases associated with expression of EBPH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding EBPH for the treatment of diseases associated with the expression of EBPH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding EBPH.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:150285 USPATFULL
TITLE: Human eosinophil-derived basic protein
INVENTOR(S): Akerblom, Ingrid E., Redwood City, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United

States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6143867		20001107
APPLICATION INFO.:	US 1998-40483		19980317 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-740036, filed on 23 Oct 1996		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Christina Y.		
ASSISTANT EXAMINER:	VanderVegt, F. Pierre		
LEGAL REPRESENTATIVE:	Incyte Genomics, Inc.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	2241		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 21 OF 21 USPATFULL on STN

TI Human eosinophil-derived basic protein

AB The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and agonists, antibodies or antagonists specifically binding EBPH, in the prevention and treatment of diseases associated with expression of EBPH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding EBPH for the treatment of diseases associated with the expression of EBPH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding EBPH.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:28197 USPATFULL
TITLE:	Human eosinophil-derived basic protein
INVENTOR(S):	Akerblom, Ingrid E., Redwood City, CA, United States
PATENT ASSIGNEE(S):	Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5728820		19980317
APPLICATION INFO.:	US 1996-740036		19961023 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Saunders, David		
ASSISTANT EXAMINER:	VanderVegt, F. Pierre		
LEGAL REPRESENTATIVE:	Billings, Lucy J.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2148		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e bigalke, h/au

E1	2		BIGALKE THOMAS/AU
E2	4		BIGALKE U/AU
E3	0	-->	BIGALKE, H/AU
E4	4		BIGALL E J/AU
E5	3		BIGALL EVAN J/AU
E6	1		BIGALL K/AU

```
E7              8      BIGALL K D/AU
E8              4      BIGALL KLAUS D/AU
E9              4      BIGALL KLAUS DIETER/AU
E10             1      BIGALL W/AU
E11             1      BIGALL WADE/AU
E12             1      BIGALLET J P/AU

=> e fervert,j/au
E1              5      FERVERS WOLFGANG/AU
E2              1      FERVERT J/AU
E3              0 --> FERVERT,J/AU
E4              1      FERVEUR B/AU
E5              3      FERVEUR BERNARD/AU
E6              2      FERVEUR BERNARD R P/AU
E7              1      FERVEUR BERNARD RAYMOND PIERRE/AU
E8              7      FERVEUR C/AU
E9              1      FERVEUR E/AU
E10             1      FERVEUR ELISABETH/AU
E11            43      FERVEUR J F/AU
E12            25      FERVEUR JEAN FRANCOIS/AU

=> s tetanus toxin
L11          9222 TETANUS TOXIN

=> s clostriduim and light chain
L12             0 CLOSTRIDUIM AND LIGHT CHAIN

=> s l11 and light chain
L13           802 L11 AND LIGHT CHAIN

=> s l13 and antibody
L14           384 L13 AND ANTIBODY

=> s l14 and IgA
L15            99 L14 AND IGA

=> d his

     (FILE 'HOME' ENTERED AT 11:15:39 ON 17 MAY 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, HCAPLUS,
     JICST-EPLUS' ENTERED AT 11:16:09 ON 17 MAY 2004
L1            2882 S HYBRID PROTEIN AND PROTEASE
L2            6604 S HYBRID PROTEIN AND ANTIBODY
L3            2111 S L2 AND L1
L4            1445 S L3 AND IGG
L5               0 S CLOSTRIDUM BOTULINUM NEUROTOXIN
L6              37 S CLOSTRIDUM BOTULINUM
L7               0 S L6 AND L4
L8               1 S L6 AND MAST CELL
L9               0 S L4 AND MASTOCYTE
L10             21 S L4 AND BASOPHIL
                   E BIGALKE, H/AU
                   E FERVERT,J/AU
L11           9222 S TETANUS TOXIN
L12              0 S CLOSTRIDUIM AND LIGHT CHAIN
L13            802 S L11 AND LIGHT CHAIN
L14            384 S L13 AND ANTIBODY
L15             99 S L14 AND IGA

=> s l15 and l10
L16             0 L15 AND L10

=> s mast cell
```

```
L17       54498 MAST CELL

=> s l17 and degranulation
L18        9477 L17 AND DEGRANULATION

=> s l18 and inhibition
L19        2409 L18 AND INHIBITION

=> s l19 and neurotoxin
L20          20 L19 AND NEUROTOXIN

=> d l20 ti abs ibib tot

L20  ANSWER 1 OF 20     MEDLINE on STN
TI   The promotion of eosinophil degranulation and adhesion to
     conjunctival epithelial cells by IgE-activated conjunctival mast cells.
AB   BACKGROUND: Allergen-mediated mast cell activation is
     a key feature of ocular allergic diseases.  Evidence of eosinophil-derived
     mediators in tears and conjunctival biopsy specimens has been associated
     with chronic ocular allergic inflammation.  OBJECTIVE: To examine the role
     of conjunctival mast cell mediators in eosinophil
     adhesion to conjunctival epithelial cells and eosinophil
     degranulation.  METHODS: Conjunctival cells were obtained by
     enzymatic digestion of cadaveric conjunctival tissues.  Eosinophils were
     obtained from peripheral blood samples using negative magnetic bead
     selection.  The effect of IgE-activated mast cell
     supernates on eosinophil degranulation and adherence to
     epithelial cells was compared with supernates obtained from mast cells
     pretreated with a degranulation inhibitor (olopatadine).
     Eosinophil adhesion was measured by eosinophil peroxidase assay, and
     eosinophil degranulation was measured by eosinophil-derived
     neurotoxin radioimmunoassay.  RESULTS: IgE-activated conjunctival
     mast cell supernates stimulated adhesion of eosinophils
     to epithelial cells (20.4% +/- 6.3% vs 3.1% +/- 1.0%; P = .048).
     Degranulation was not required for this process (no effect of
     olopatadine).  IgE-activated mast cell supernates
     stimulated eosinophil-derived neurotoxin release (108.89 +/-
     8.27 ng/10(6) cells vs 79.45 +/- 5.21 ng/10(6) cells for controls, P =
     .02), which was significantly inhibited by pretreatment of mast cells with
     a degranulation inhibitor (79.22 +/- 4.33 ng/10(6) cells vs
     61.09 +/- 5.39 ng/10(6) cells for olopatadine pretreated and untreated,
     respectively, P = .02).  CONCLUSIONS: Mediators released from conjunctival
     mast cells promote eosinophil adhesion to conjunctival epithelial cells
     and eosinophil degranulation.  Degranulation
     inhibition studies suggest that different mast
     cell mediators are involved in regulation of these events.
ACCESSION NUMBER:    2004055206     MEDLINE
DOCUMENT NUMBER:     PubMed ID: 14756467
TITLE:               The promotion of eosinophil degranulation and
                     adhesion to conjunctival epithelial cells by IgE-activated
                     conjunctival mast cells.
AUTHOR:              Cook Ellen B; Stahl James L; Sedgwick Julie B; Barney Neal
                     P; Graziano Frank M
CORPORATE SOURCE:    Department of Medicine, University of Wisconsin-Madison,
                     School of Medicine, Madison, Wisconsin, USA.
CONTRACT NUMBER:     EY 012526 (NEI)
SOURCE:              Annals of allergy, asthma & immunology : official
                     publication of the American College of Allergy, Asthma, &
                     Immunology, (2004 Jan) 92 (1) 65-72.
                     Journal code: 9503580. ISSN: 1081-1206.
PUB. COUNTRY:        United States
DOCUMENT TYPE:       Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:            English
FILE SEGMENT:        Priority Journals
```

ENTRY MONTH: 200402
ENTRY DATE: Entered STN: 20040204
Last Updated on STN: 20040225
Entered Medline: 20040224

L20 ANSWER 2 OF 20 MEDLINE on STN
TI Soluble NSF attachment protein receptors (SNAREs) in RBL-2H3 mast cells: functional role of syntaxin 4 in exocytosis and identification of a vesicle-associated membrane protein 8-containing secretory compartment.
AB Mast cells upon stimulation through high affinity IgE receptors massively release inflammatory mediators by the fusion of specialized secretory granules (related to lysosomes) with the plasma membrane. Using the RBL-2H3 rat **mast cell** line, we investigated whether granule secretion involves components of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) machinery. Several isoforms of each family of SNARE proteins were expressed. Among those, synaptosome-associated protein of 23 kDa (SNAP23) was central in SNARE complex formation. Within the syntaxin family, syntaxin 4 interacted with SNAP23 and all vesicle-associated membrane proteins (VAMPs) examined, except tetanus **neurotoxin** insensitive VAMP (TI-VAMP). Overexpression of syntaxin 4, but not of syntaxin 2 nor syntaxin 3, caused **inhibition** of FcepsilonRI-dependent exocytosis. Four VAMP proteins, i.e., VAMP2, cellubrevin, TI-VAMP, and VAMP8, were present on intracellular membrane structures, with VAMP8 residing mainly on mediator-containing secretory granules. We suggest that syntaxin 4, SNAP23, and VAMP8 may be involved in regulation of **mast cell** exocytosis. Furthermore, these results are the first demonstration that the nonneuronal VAMP8 isoform, originally localized on early endosomes, is present in a regulated secretory compartment.
ACCESSION NUMBER: 2000281674 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10820264
TITLE: Soluble NSF attachment protein receptors (SNAREs) in RBL-2H3 mast cells: functional role of syntaxin 4 in exocytosis and identification of a vesicle-associated membrane protein 8-containing secretory compartment.
AUTHOR: Paumet F; Le Mao J; Martin S; Galli T; David B; Blank U; Roa M
CORPORATE SOURCE: Unite d'Immuno-Allergie, Institut Pasteur, Paris, France.
SOURCE: Journal of immunology (Baltimore, Md. : 1950), (2000 Jun 1) 164 (11) 5850-7.
Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200006
ENTRY DATE: Entered STN: 20000629
Last Updated on STN: 20020420
Entered Medline: 20000621

L20 ANSWER 3 OF 20 USPATFULL on STN
TI Sphingolipid derivatives and their methods of use
AB Derivatives of sphingolipids of the formula: ##STR1##

are provided wherein the substituents are as defined in the specification and wherein there is at least one R.sup.2 substituent in the sphingolipid derivative. The compounds are useful in the treatment of of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the **inhibition** of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that

includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof. Further, the invention provides a method for treating bacterial infections, including those that influence colon cancer and other disorders of the intestine, that includes administering an effective amount of one of the active compounds identified herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:51781 USPATFULL
TITLE: Sphingolipid derivatives and their methods of use
INVENTOR(S): Liotta, Dennis C., McDonough, GA, UNITED STATES
Merrill, Alfred H., JR., Dunwoody, GA, UNITED STATES
Keane, Thomas E., Dunwoody, GA, UNITED STATES
Bhalla, Kapil N., Atlanta, GA, UNITED STATES
Schmelz, Eva M., Atlanta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004039212	A1	20040226
APPLICATION INFO.:	US 2003-647801	A1	20030825 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-249211, filed on 12 Feb 1999, GRANTED, Pat. No. US 6610835

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-74536P	19980212 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 4250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 4 OF 20 USPATFULL on STN
TI Proteins and nucleic acids encoding same
AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:44501 USPATFULL
TITLE: Proteins and nucleic acids encoding same
INVENTOR(S): Tchernev, Velizar T., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Miller, Charles E., Hill Drive, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Gusev, Vladimir Y., UNITED STATES

Colman, Steven D., Guilford, CT, UNITED STATES
Wolenc, Adam Ryan, New Haven, CT, UNITED STATES
Pena, Carol E. A., Guilford, CT, UNITED STATES
Furtak, Katarzyna, Anosia, CT, UNITED STATES
Grosse, William M., Bransford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004033493	A1	20040219	
APPLICATION INFO.:	US 2002-72012	A1	20020131	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-267459P	20010208	(60)
	US 2001-266975P	20010207	(60)
	US 2001-267057P	20010207	(60)
	US 2001-266767P	20010205	(60)
	US 2001-266406P	20010202	(60)
	US 2001-265395P	20010131	(60)
	US 2001-265412P	20010131	(60)
	US 2001-265517P	20010131	(60)
	US 2001-265514P	20010131	(60)
	US 2001-267823P	20010209	(60)
	US 2001-268974P	20010215	(60)
	US 2001-271855P	20010227	(60)
	US 2001-271839P	20010227	(60)
	US 2001-273046P	20010302	(60)
	US 2001-272788P	20010302	(60)
	US 2001-275989P	20010314	(60)
	US 2001-275925P	20010314	(60)
	US 2001-275947P	20010314	(60)
	US 2001-275950P	20010314	(60)
	US 2001-276450P	20010315	(60)
	US 2001-276448P	20010315	(60)
	US 2001-276397P	20010316	(60)
	US 2001-276768P	20010316	(60)
	US 2001-278652P	20010320	(60)
	US 2001-278775P	20010326	(60)
	US 2001-278778P	20010326	(60)
	US 2001-279882P	20010329	(60)
	US 2001-279884P	20010329	(60)
	US 2001-280147P	20010330	(60)
	US 2001-283083P	20010411	(60)
	US 2001-282992P	20010411	(60)
	US 2001-285133P	20010420	(60)
	US 2001-285749P	20010423	(60)
	US 2001-288327P	20010503	(60)
	US 2001-288504P	20010503	(60)
	US 2001-294047P	20010529	(60)
	US 2001-294473P	20010530	(60)
	US 2001-296964P	20010608	(60)
	US 2001-298959P	20010618	(60)
	US 2001-299324P	20010619	(60)
	US 2001-312020P	20010813	(60)
	US 2001-312908P	20010816	(60)
	US 2001-312889P	20010816	(60)
	US 2001-313930P	20010821	(60)
	US 2001-315470P	20010828	(60)
	US 2001-316447P	20010831	(60)
	US 2001-318115P	20010907	(60)

	US 2001-318118P	20010907 (60)
	US 2001-318740P	20010912 (60)
	US 2001-323379P	20010919 (60)
	US 2001-330308P	20011018 (60)
	US 2001-330245P	20011018 (60)
	US 2001-332701P	20011114 (60)
	US 2001-271664P	20010226 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ivor R. Elrifi, Ph.D., Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, P.C., One Financial Center, Boston, MA, 02111	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
LINE COUNT:	59681	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 5 OF 20 USPATFULL on STN

TI Immune modulatory activity of human ribonucleases

AB Human extracellular ribonucleases (RNases) are widely distributed in various organs and body fluids and together with other members of the mammalian RNase A superfamily. In addition to their RNase activity, several RNases have been shown to have special biological actions, i.e., antitumor, antiviral and angiogenic properties. However, the molecular mechanisms of such activities are unclear. Using protein microarrays amplified rolling circle amplification (RCA), we investigated the effects of EDN (Rnase 2), ECP (Rnase 3) and RNase 1 on leukocytes cytokine production. We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with different combinations of RNases and RNase inhibitors. Members of human ribonuclease family (such as Rnase 1, hEDN (Rnase 2) and Rnase 3) induced expression of certain sets of cytokines in human leukocytes, including ENA-78, EOT2, BLC, GDNF, 1309, IFN-α, IFN-γ, IL-10, IL-12P40, IL-12p70, IL-13, IL-16, IL-18, IL-1β, IL-1ra, IL-2Sra, IL-3, IL-6, IL-6sR, IL-7, IL-8, IP-10, MCP-1, MCP-2, MCP-3, MCSF, MIG, MDC, MIP-1α, MIP-1β, MPIF-1, NAP-2, RANTES, sCD23, OSM, TARC, TNF-α, TNF-R1 and uPAR. Thus members of the Rnase superfamily are therapeutic targets for treatment of inflammatory diseases and clinical conditions. **Inhibition** or augmentation of Rnase expression is used to modulate the immune system and is beneficial for host defense against various diseases and is exploited as an adjuvant. The expression of Rnases is a diagnostic marker for inflammation related conditions and is used to determine various disease stages. In addition, expression of cytokines, chemokines, growth factors is used to monitor efficacy of Rnase-base therapies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:12983 USPATFULL			
TITLE:	Immune modulatory activity of human ribonucleases			
INVENTOR(S):	Fu, Qin, Baltimore, MD, UNITED STATES Tchernev, Velizar, Branford, CT, UNITED STATES Satyaraj, Ebenezer, Hamden, CT, UNITED STATES Patel, Dhavalkumar D., Durham, NC, UNITED STATES Kingsmore, Stephen F., Guilford, CT, UNITED STATES Schweitzer, Barry, Woodbridge, CT, UNITED STATES			
PATENT ASSIGNEE(S):	Molecular Staging, Inc., New Haven, CT, 06511 (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009503	A1	20040115	
APPLICATION INFO.:	US 2003-396317	A1	20030326	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-393110P	20020703 (60)
	US 2002-394511P	20020710 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 6 OF 20 USPATFULL on STN
TI Tumor necrosis factor receptor 2
AB The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:4504 USPATFULL
TITLE: Tumor necrosis factor receptor 2
INVENTOR(S): Stanton, Jr., Vincent P., Belmont, MA, United States
PATENT ASSIGNEE(S): Nuvelo, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673908	B1	20040106
APPLICATION INFO.:	US 2001-968455		20011001 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-649035, filed on 25 Aug 2000 Continuation-in-part of Ser. No. US 2000-590749, filed on 8 Jun 2000, now abandoned Continuation-in-part of Ser. No. US 2000-495780, filed on 1 Feb 2000, now abandoned Continuation-in-part of Ser. No. US 2000-492712, filed on 27 Jan 2000, now abandoned Continuation-in-part of Ser. No. WO 2000-US1392, filed on 20 Jan 2000 Continuation-in-part of Ser. No. US 968455 Continuation-in-part of Ser. No. US 1999-451252, filed on 29 Nov 1999, now abandoned Continuation-in-part of Ser. No. US 1999-427835, filed on 26 Oct 1999, now abandoned Continuation-in-part of Ser. No. US 1999-414330, filed on 6 Oct 1999, now abandoned Continuation-in-part of Ser. No. US 1999-389993, filed on 3 Sep 1999, now abandoned Continuation-in-part of Ser. No. US 1999-370841, filed on 9 Aug 1999, now abandoned Continuation-in-part of Ser. No. US 1999-300747, filed on 26 Apr 1999, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131334P	19990426 (60)
	US 1999-131191P	19990426 (60)
	US 1999-121047P	19990222 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Benzion, Gary
ASSISTANT EXAMINER: Chakrabarti, Arun Kr.
LEGAL REPRESENTATIVE: Fish & Richardson P.C.

NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 17463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 7 OF 20 USPATFULL on STN
TI Sphingolipid derivatives and their methods of use
AB Derivatives of sphingolipids of the formula: ##STR1##

are provided wherein the substituents are as defined in the specification and wherein there is at least one R.sup.2 substituent in the sphingolipid derivative. The compounds are useful in the treatment of of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the **inhibition** of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof. Further, the invention provides a method for treating bacterial infections, including those that influence colon cancer and other disorders of the intestine, that includes administering an effective amount of one of the active compounds identified herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:228401 USPATFULL
TITLE: Sphingolipid derivatives and their methods of use
INVENTOR(S): Liotta, Dennis C., McDonough, GA, United States
Merrill, Jr., Alfred H., Stone Mountain, GA, United States
Keane, Thomas E., Dunwoody, GA, United States
Bhalla, Kapil N., Atlanta, GA, United States
Schmelz, Eva M, Atlanta, GA, United States(4)
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6610835	B1	20030826	
APPLICATION INFO.:	US 1999-249211		19990212	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-74536P	19980212 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Wilson, James O.
ASSISTANT EXAMINER: Maier, Leigh C.
LEGAL REPRESENTATIVE: King & Spalding LLP, Knowles, Sherry M.
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 4123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 8 OF 20 USPATFULL on STN
TI Regulation of human sphingosine kinase-like protein
AB Reagents which regulate human sphingosine kinase-like protein activity and reagents which bind to human sphingosine kinase-like gene products can be used to regulate intracellular signaling and consequently cell proliferation and apoptosis. Such regulation is particularly useful for

treating cancer, allergies including but not limited to asthma, autoimmune diseases such as rheumatoid arthritis, and central and peripheral nervous system disorders, such as Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181699 USPATFULL
TITLE: Regulation of human sphingosine kinase-like protein
INVENTOR(S): Kossida, Sophia, Toulouse, FRANCE
Encinas, Jeffrey, Nara, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125533	A1	20030703	
APPLICATION INFO.:	US 2001-969896	A1	20011004	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-238005P	20001006	(60)
	US 2001-314113P	20010823	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
NUMBER OF CLAIMS: 65
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 3848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 9 OF 20 USPATFULL on STN
TI Human cDNAs and proteins and uses thereof
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:173153 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003118997	A1	20030626	
APPLICATION INFO.:	US 2001-978418	A1	20011015	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-311305P	20010810	(60)
	US 2001-314734P	20010824	(60)
	US 2001-318204P	20010907	(60)
	US 2001-326470P	20011001	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Saliwanchik, Lloyd & Saliwanchik, Frank C. Eisenchenk, Ph. D, 2421 N.W. 41st street, Suite A-1, Gainesville, FL, 32606-6669
NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1
LINE COUNT: 15316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 10 OF 20 USPATFULL on STN
TI Isolated polypeptides and compositions from the venom of P. transvaalicus and methods of use
AB The invention provides isolated polypeptides from the venom of the scorpion P. transvaalicus. The invention also provides novel scorpion antivenom compositions derived from such polypeptides, as well as methods for isolating the polypeptides and preparing scorpion antivenom compositions. The isolated polypeptides can be used to produce pharmaceutical compositions useful for treating diseases and conditions associated with ion channel function or kinin activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:166036 USPATFULL
TITLE: Isolated polypeptides and compositions from the venom of P. transvaalicus and methods of use
INVENTOR(S): Hammock, Bruce D., Davis, CA, UNITED STATES
Inceoglu, Bora, Cankaya, TURKEY

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003113892	A1	20030619	
APPLICATION INFO.:	US 2002-264480	A1	20021004	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-327602P	20011004	(60)
	US 2002-393070P	20020628	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 3768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 11 OF 20 USPATFULL on STN
TI Composition comprising soy protein, dietary fibers and a phytoestrogen compound and use thereof in the prevention and/or treatment of various diseases
AB A composition comprising (a) soy protein, (b) a phytoestrogen compound, and (c) dietary fibres is provided. The soy protein (a) is present in an amount of at least 45 weight percent of the total protein content of the composition, said total protein content providing at least 15 percent of the total energy content of the composition. The phytoestrogen compound (b) is preferably a naturally occurring isoflavone and is present in an amount of more than 0.10 weight percent of the soy protein, and the dietary fibres (c) are preferably soybean fibres and are present in an amount of more than 6 weight percent of the total weight of the nutritional composition on a dry basis. The composition is useful for treating various diseases. Alternatively, the phytoestrogen is more than 0.55 weight percent of the soy protein and the dietary fibers are more than 4 weight percent of the total weight.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:165536 USPATFULL
TITLE: Composition comprising soy protein, dietary fibers and a phytoestrogen compound and use thereof in the prevention and/or treatment of various diseases

INVENTOR(S): Hoie, Lars Henrik, London, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003113390	A1	20030619
APPLICATION INFO.:	US 2002-254636	A1	20020926 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-502598, filed on 11 Feb 2000, PENDING Continuation-in-part of Ser. No. WO 1999-DK655, filed on 25 Nov 1999, UNKNOWN Continuation of Ser. No. WO 1999-IB1992, filed on 25 Nov 1999, UNKNOWN Continuation of Ser. No. WO 1999-IB1997, filed on 25 Nov 1999, UNKNOWN Continuation of Ser. No. WO 1999-IB1998, filed on 25 Nov 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1998-1555	19981125
	DK 1999-855	19990616
	DK 1998-1556	19981125
	DK 1999-856	19990616
	DK 1998-1557	19981125
	US 1998-110505P	19981201 (60)
	US 1998-110506P	19981201 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., 624 Ninth Street, N.W., Washington, DC, 20001
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 12 OF 20 USPATFULL on STN
TI Hybrid protein for inhibiting the **degranulation** of mastocytes and the use thereof
AB A hybrid protein contains a protein that binds to a receptor of mastocytes and basophils and is endocyted by them. The protein can be IgE; IgE fragment; IgE Fc fragment; antibody against IgE receptor of mastocytes and basophils; fragment of the antibody against the IgE receptor of mastocytes and basophils; antibody against mastocyte specific potassium channel; and **mast cell** degranulating peptide. The hybrid protein also contains a protease cleaving proteins of the secretion process of the mastocytes and basophils so as to inhibit the secretion process without killing the mastocytes and basophils. The protease can be light chain Clostridium botulinum toxin; proteolytically active fragment of the light chain of a Clostridium botulinum toxin containing an amino acid sequence His-Xaa-Xaa-Xaa-His-Xaa-Xaa-His wherein Xaa is an amino acid; light chain of the tetanus toxin; proteolytically active fragment of the light chain of the tetanus toxin containing His-Asp-Leu-Ile-His-Val-Leu-His; IgA protease of Neisseria gonorrhoeae; and proteolytic domain of the IgA protease of Neisseria gonorrhoeae.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:86306 USPATFULL
TITLE: Hybrid protein for inhibiting the **degranulation** of mastocytes and the use thereof
INVENTOR(S): Bigalke, Hans, Hannover, GERMANY, FEDERAL REPUBLIC OF
Frevert, Jurgen, Berlin, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): BioteCon Gesellschaft fur biotechnologische Entwicklung und consulting mbH, Berlin, DE, 10589 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059912	A1	20030327
APPLICATION INFO.:	US 2002-64903	A1	20020827 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-700540, filed on 19 Jan 2001, PENDING A 371 of International Ser. No. WO 1999-EP3272, filed on 12 May 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1998-19821285	19980513

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GUDRUN E. HUCKETT, LONSSTR. 53, WUPPERTAL, 42289
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 576
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 13 OF 20 USPATFULL on STN
TI Cytotoxin (non-**neurotoxin**) for the treatment of human headache disorders and inflammatory diseases
AB Pharmaceutical applications of a chemodenervating agent reduce pain by altering release of pain- and inflammation-mediating autocoids, with a duration of action between 12-24 weeks. The limiting factor in dosing for this application is weakness and paralysis created by higher doses of the chemodenervating pharmaceutical mediated by action of the **neurotoxin** component of this chemodenervating pharmaceutical. The invention described herein represents a novel mechanism and pharmaceutical formulation which eliminates the **neurotoxin** component of the chemodenervating pharmaceutical, while retaining the cytotoxin component which provides an essential bioeffect for the relief of pain and inflammation. The invention allows for improvement in administering the pharmaceutical agent for the reduction of pain and/or inflammation without causing muscular weakness and paralysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:329485 USPATFULL
TITLE: Cytotoxin (non-**neurotoxin**) for the treatment of human headache disorders and inflammatory diseases
INVENTOR(S): Borodic, Gary E., Canton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002187164	A1	20021212
APPLICATION INFO.:	US 2002-212657	A1	20020805 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-458784, filed on 10 Dec 1999, GRANTED, Pat. No. US 6429189
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michael N. Nitabach, Milbank, Tweed, Hadley & McCloy LLP, 1 Chase Manhattan Plaza, New York, NY, 10005
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 576
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 14 OF 20 USPATFULL on STN
TI Cytotoxin (non-**neurotoxin**) for the treatment of human headache disorders and inflammatory diseases
AB Pharmaceutical applications of a chemodenervating agent reduce pain by altering release of pain and inflammation-mediating autocoids, with a duration of action between 12-24 weeks. The limiting factor in dosing

for this application is weakness and paralysis created by higher doses of the chemodenervating pharmaceutical. This weakness and paralysis is mediated by action of the **neurotoxin** component of the chemodenervating pharmaceutical. The invention described herein represents a novel mechanism and pharmaceutical formulation which eliminates the **neurotoxin** component of the chemodenervating pharmaceutical, while retaining the cytotoxin component which provides an essential bioeffect for the relief of pain and inflammation. The invention allows for improvement in administering the pharmaceutical agent for the reduction of pain and/or inflammation without causing muscular weakness and paralysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:194871 USPATFULL
TITLE:	Cytotoxin (non-**neurotoxin**) for the treatment of human headache disorders and inflammatory diseases
INVENTOR(S):	Borodic, Gary E., Canton, MA, United States
PATENT ASSIGNEE(S):	Botulinum Toxin Research Associates, Inc., Qunicy, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6429189	B1	20020806	
APPLICATION INFO.:	US 1999-458784		19991210	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Cochrane Carlson, Karen			
ASSISTANT EXAMINER:	Robinson, Hope A.			
LEGAL REPRESENTATIVE:	Milbank, Tweed, Hadley & McCloy LLP			
NUMBER OF CLAIMS:	29			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 2 Drawing Page(s)			
LINE COUNT:	758			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 15 OF 20 USPATFULL on STN
TI IL-5 targeted ribozymes
AB Enzymatic RNA molecules which cleave IL-5 mRNA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:27078 USPATFULL
TITLE:	IL-5 targeted ribozymes
INVENTOR(S):	Sullivan, Sean, Alameda, CA, United States Draper, Kenneth G., Boulder, CO, United States McSwiggen, James, Boulder, CO, United States Stinchcomb, Dan T., Boulder, CO, United States
PATENT ASSIGNEE(S):	Ribozyme Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5616488		19970401	
APPLICATION INFO.:	US 1994-319492		19941007	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-989849, filed on 7 Dec 1992, now abandoned And Ser. No. US 1993-8895, filed on 19 Jan 1993, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	LeGuyader, John			
LEGAL REPRESENTATIVE:	Lyon & Lyon			
NUMBER OF CLAIMS:	22			
EXEMPLARY CLAIM:	1,9,10			
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 6 Drawing Page(s)			
LINE COUNT:	2361			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 16 OF 20 USPATFULL on STN
TI Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena
AB Hydroxyamines N-acyl derivatives with benzochroman or 2,3-dihydrobenzofuran carboxy acids and relative pharmaceutical composition for the therapeutic treatment of those CNS, vascular, cardiovascular, dermatologic and ophthalmic pathologies wherein it is important to associate an inflammatory modulation effect to an antioxidant activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	96:1228 USPATFULL
TITLE:	Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena
INVENTOR(S):	Della Valle, Francesco, Padova, Italy Lorenzi, Silvana, Padova, Italy Marcolongo, Gabriele, Carrara S. Giorgio, Italy
PATENT ASSIGNEE(S):	LifeGroup S.p.A., Rome, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5480645		19960102	
APPLICATION INFO.:	US 1993-175233		19931229	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1992-MI2997	19921231

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	McKane, Joseph K.
LEGAL REPRESENTATIVE:	Stevens, Davis, Miller & Mosher
NUMBER OF CLAIMS:	21
EXEMPLARY CLAIM:	1
LINE COUNT:	1170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 17 OF 20 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI The promotion of eosinophil **degranulation** and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells.
AB Background: Allergen-mediated **mast cell** activation is a key feature of ocular allergic diseases. Evidence of eosinophil-derived mediators in tears and conjunctival biopsy specimens has been associated with chronic ocular allergic inflammation. Objective: To examine the role of conjunctival **mast cell** mediators in eosinophil adhesion to conjunctival epithelial cells and eosinophil **degranulation**. Methods: Conjunctival cells were obtained by enzymatic digestion of cadaveric conjunctival tissues. Eosinophils were obtained from peripheral blood samples using negative magnetic bead selection. The effect of IgE-activated **mast cell** supernates on eosinophil **degranulation** and adherence to epithelial cells was compared with supernates obtained from mast cells pretreated with a **degranulation** inhibitor (olopatadine). Eosinophil adhesion was measured by eosinophil peroxidase assay, and eosinophil **degranulation** was measured by eosinophil-derived **neurotoxin** radioimmunoassay. Results: IgE-activated conjunctival **mast cell** supernates stimulated adhesion of eosinophils to epithelial cells (20.4% ± 6.3% vs 3.1% ± 1.0%; P = .048). **Degranulation** was not required for this process (no effect of olopatadine). IgE-activated **mast cell** supernates

stimulated eosinophil-derived **neurotoxin** release (108.89 ± 8.27 ng/10(6) cells vs 79.45 ± 5.21 ng/10(6) cells for controls, P = .02), which was significantly inhibited by pretreatment of mast cells with a **degranulation** inhibitor (79.22 ± 4.33 ng/10(6) cells vs 61.09 ± 5.39 ng/10(6) cells for olopatadine pretreated and untreated, respectively, P = .02). Conclusions: Mediators released from conjunctival mast cells promote eosinophil adhesion to conjunctival epithelial cells and eosinophil **degranulation**. **Degranulation inhibition** studies suggest that different **mast cell** mediators are involved in regulation of these events.

ACCESSION NUMBER: 2004040668 EMBASE
TITLE: The promotion of eosinophil **degranulation** and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells.
AUTHOR: Cook E.B.; Stahl J.L.; Sedgwick J.B.; Barney N.P.; Graziano F.M.
CORPORATE SOURCE: Dr. J.L. Stahl, University of Wisconsin-Madison, H6/361 Clinical Science Center, 600 Highland Ave, Madison, WI 53792, United States. jlstahl@medicine.wisc.edu
SOURCE: Annals of Allergy, Asthma and Immunology, (2004) 92/1 (65-72).
Refs: 43
ISSN: 1081-1206 CODEN: ALAIF6
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 026 Immunology, Serology and Transplantation
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

L20 ANSWER 18 OF 20 EMBASE
on STN
TI Eosinophil granule proteins inhibit substance P-induced histamine release from human skin mast cells.
AB We have investigated the activity of the four principal cationic proteins of the eosinophil granules, major basic protein (MBP), eosinophil peroxidase (EPO), eosinophil-derived **neurotoxin**, and eosinophil cationic protein on histamine release from human skin mast cells. These four cationic proteins, over the concentration range of 10 to 200 µg/ml, did not induce significant histamine release, nor did they prime anti-IgE-induced histamine release from human skin mast cells significantly. However, a brief incubation (15 minutes) of two of the four principal eosinophil granule proteins, MBP and EPO, at concentrations of 50 to 200 µg/ml, caused a significant concentration- related **inhibition** of histamine release induced by 30 µmol/L substance P. The concentrations producing 50% **inhibition** for MBP and EPO on substance P- induced histamine release were 30 µg/ml and 100 µg/ml, respectively. This inhibitory effect appears to be a direct effect of these proteins on skin mast cells because purified (78% to 85%) skin mast cells displayed a similar response to MBP and EPO (n = 4). Also, when skin mast cells were incubated with 100 µg/ml MBP and EPO for 15 minutes and washed twice before activation by substance P, the inhibitory effect was not altered. These two proteins also inhibited histamine release induced by 10 µg/ml compound 48/80. These results suggest that MBP and EPO affect the same binding site(s) on skin mast cells as those of substance P.

ACCESSION NUMBER: 94158034 EMBASE
DOCUMENT NUMBER: 1994158034
TITLE: Eosinophil granule proteins inhibit substance P-induced histamine release from human skin mast cells.
AUTHOR: Okayama Y.; El-Lati S.G.; Leiferman K.M.; Church M.K.
CORPORATE SOURCE: Immunopharmacology Group, Clinical Pharmacology, Southampton General Hospital,Southampton SO9 4XY, United Kingdom

SOURCE: Journal of Allergy and Clinical Immunology, (1994) 93/5 (900-909).
ISSN: 0091-6749 CODEN: JACIBY
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 003 Endocrinology
026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English

L20 ANSWER 19 OF 20 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI Intestinal permeability in allergic rats: Nerve involvement in antigen-induced changes.

AB In vivo uptake of the probe 51Cr-labeled EDTA from the jejunum of egg albumin (EA)-sensitized rats was compared with controls at baseline and after intraluminal antigen challenge. Probe recovery in blood was 60-80% greater in sensitized animals during the baseline period, suggesting that sensitization resulted in increased intestinal permeability. Sensitized, but not control, rats demonstrated a 15-fold increase in 51Cr-EDTA uptake after intraluminal antigen; no change occurred with an unrelated protein. Macromolecular recovery was also enhanced in sensitized animals, since serum levels of immunoreactive EA were elevated 14-fold compared with controls. Antigen challenge was accompanied by biochemical (protease release) and morphological (reduced numbers) evidence of **mast cell degranulation** in sensitized rats. The **neurotoxin** tetrodotoxin (applied directly to ligated jejunal segments) inhibited EA-induced uptake of 51Cr-EDTA and antigen. In isolated jejunum from sensitized rats, tetrodotoxin reduced secretory responses to luminal, but not serosal, antigen. These results indicate that neural factors may influence the uptake of molecules from the gut lumen during intestinal anaphylaxis.

ACCESSION NUMBER: 93124760 EMBASE
DOCUMENT NUMBER: 1993124760
TITLE: Intestinal permeability in allergic rats: Nerve involvement in antigen- induced changes.
AUTHOR: Crowe S.E.; Soda K.; Stanisz A.M.; Perdue M.H.
CORPORATE SOURCE: Div. of Gastroenterology, 4.106 McCullough Bldg., Univ. of Texas Medical Branch,Galveston, TX 77555-0764, United States
SOURCE: American Journal of Physiology - Gastrointestinal and Liver Physiology, (1993) 264/4 27-4 (G617-G623).
ISSN: 0002-9513 CODEN: APGPDF
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 002 Physiology
048 Gastroenterology
LANGUAGE: English
SUMMARY LANGUAGE: English

L20 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Soluble NSF attachment protein receptors (SNAREs) in RBL-2H3 mast cells: functional role of syntaxin 4 in exocytosis and identification of a vesicle-associated membrane protein 8-containing secretory compartment

AB Mast cells upon stimulation through high affinity IgE receptors massively release inflammatory mediators by the fusion of specialized secretory granules (related to lysosomes) with the plasma membrane. Using the RBL-2H3 rat **mast cell** line, the authors investigated whether granule secretion involves components of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) machinery. Several isoforms of each family of SNARE proteins were expressed. Among those, synaptosome-associated protein of 23 kDa (SNAP23) was central in SNARE complex formation. Within the syntaxin family,

syntaxin 4 interacted with SNAP23 and all vesicle-associated membrane proteins (VAMPs) examined, except tetanus **neurotoxin** insensitive VAMP (TI-VAMP). Overexpression of syntaxin 4, but not of syntaxin 2 nor syntaxin 3, caused **inhibition** of FcεRI-dependent exocytosis. Four VAMP proteins, i.e., VAMP2, cellubrevin, TI-VAMP, and VAMP8, were present on intracellular membrane structures, with VAMP8 residing mainly on mediator-containing secretory granules. The authors suggest that syntaxin 4, SNAP23, and VAMP8 may be involved in regulation of **mast cell** exocytosis. Furthermore, these results are the first demonstration that the nonneuronal VAMP8 isoform, originally localized on early endosomes, is present in a regulated secretory compartment.

ACCESSION NUMBER: 2000:373559 HCAPLUS
DOCUMENT NUMBER: 133:118873

TITLE: Soluble NSF attachment protein receptors (SNAREs) in RBL-2H3 mast cells: functional role of syntaxin 4 in exocytosis and identification of a vesicle-associated membrane protein 8-containing secretory compartment

AUTHOR(S): Paumet, Fabienne; Le Mao, Joelle; Martin, Sophie; Galli, Thierry; David, Bernard; Blank, Ulrich; Roa, Michele

CORPORATE SOURCE: Unite d'Immuno-Allergie, Institut Pasteur, Paris, 75724, Fr.

SOURCE: Journal of Immunology (2000), 164(11), 5850-5857
CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English

REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT